Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial
The triple regimen of camrelizumab, lenvatinib, and RALOX-HAIC exhibited notable antitumor capabilities and acceptable tolerability in patients with advanced HCC. Moreover, baseline levels of IL-2, CXCL13, and CCL19 may function as predictive indicators of the response to this first-line therapeutic strategy.
Authors
- Huajin Pang (ORCID: https://orcid.org/0000-0001-7367-5701)
- Kaiyan Su
- Xiao Hu (ORCID: https://orcid.org/0000-0003-1128-4099)
- Guosheng Yuan (ORCID: https://orcid.org/0000-0002-2118-4553)
- Yongru Chen (ORCID: https://orcid.org/0000-0001-6134-3355)
- Jinzhang Chen (ORCID: https://orcid.org/0000-0003-4964-2218)
- Qi Li (ORCID: https://orcid.org/0000-0003-4780-3831)
- Yuan Li (ORCID: https://orcid.org/0000-0003-1803-6661)
- Wenli Li (ORCID: https://orcid.org/0000-0002-3532-6444)
- Peilin Zhu
- Rong Li (ORCID: https://orcid.org/0009-0000-9591-7214)
- Yuanfeng Li
- Mengya Zang
Institutions
- Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Beijing Proteome Research Center (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1159/000546575
- Citations
- 5
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 6.61
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China